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Atrial ﬁbrillation (AF) is the most common sustained arrhythmia encountered in clinical
practice. Accumulating evidence indicates a link between inﬂammation and AF, and
important advances in understanding mechanisms of AF are arising from studies of the critical
components involved in the modulation of the immunoinﬂammatory balance within the
atrium. However, molecular mechanisms remain unclear. Indeed, although preclinical and
clinical studies suggest that chronic inﬂammation may promote development of AF, the roles
of inﬂammation in the process are complex and incompletely understood. The purpose of this
review is to brieﬂy highlight current evidence on relationships between inﬂammation and AF,
and to discuss possible mechanisms of development of AF and/or possible therapeutic
approaches targeting components of the inﬂammatory response.
(J Arrhythmia 2011; 27: 106–115)
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Introduction
AF is the most common sustained arrhythmia
encountered in clinical practice. Although increasing
attention has been focused on underlying pathophy-
siological mechanisms, pathogenesis is not fully
understood and its clinical management remains
complex. Recent advances in genetics and molec-
ular biology have provided new insights into the
development of the disease, and accumulating
evidence indicates that inﬂammation may be a
predisposing factor in AF.1–3) In this review, we
will summarize and discuss the underlying molec-
ular and cellular mechanisms of the contribution of
inﬂammation to the pathogenesis of this arrhythmia
and how inﬂammation can be integrated into the
clinical context.
AF has a prevalence of 1% in the general
population,4,5) which increases with age to about
6% in people over the age of 65.6,7) Several
atherosclerotic risk factors, such as obesity, diabetes
and hypertension, have been linked with develop-
ment of AF.8–10) In atherosclerosis, these factors, or
their combination, induce endothelial dysfunction
which permits inﬂux of low-density lipoproteins
(LDL) into the arterial wall and their accumulation
in the intima. In the intima, LDL particles undergo
oxidation, and oxidised LDL and toxic peroxidation
products contribute to endothelial damage and
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stimulates endothelial cell-derived monocyte chemo-
tactic protein-1 (MCP-1) production, a major initiat-
ing event in leukocyte recruitment in atherogenesis.
This results in an immune reaction in the artery
wall and production of pro-inﬂammatory cytokines
such as interleukin-6 (IL-6), interleukin-1 (IL-1) and
tumor necrosis factor (TNF). Endothelial dysfunc-
tion increases adhesiveness of endothelium to leuko-
cytes or platelets through up-regulation of adhesion
molecules, which facilitates attachment and trans-
migration of leukocytes, monocytes and lympho-
cytes into the vascular wall.11) Localized activation
of cells releases chemokines, growth factors, and
pro-inﬂammatory cytokines. In particular, IL-6
orchestrates the temporal switch in the pattern of
leukocyte recruitment from a predominantly neutro-
philic to a mostly monocytic population. These
vascular changes can perpetuate inﬂammation and
cause destructive remodeling of the vessel structure
and formation of complex atherosclerotic lesions. A
similar inﬂammatory mechanism may be involved in
AF development in the atrium.
In early stage AF, patients may present with
paroxysmal AF, which accounts for 35–40% of all
cases, and there is 30–50% chance of conversion to a
chronic state, depending on the background heart
disease. After repeated episodes of paroxysmal AF,
the AF undergoes self-perpetuation and becomes
persistent or permanent. The majority of cases are
associated with structural abnormalities, such as
hypertensive heart disease, cardiomyopathy, valvular
disease, or ischemic heart disease, but it can also
present without obvious underlying heart disease
(lone AF). Lone AF accounts for 5–10% of AF
cases; up to 15% of individuals with lone AF may
have a familial form.12) Although the familial form
of AF is uncommon, if parents were aﬀected before
the age of 60, the parental AF can increase the risk of
AF in oﬀspring to a relative risk of 4.7.13,14) This
suggests possible involvement of genetic factors in
predisposition to the arrhythmia. Expression of a
large number of genes is associated with AF, such as
those encoding potassium channel subunits, sodium
channel subunits, sarcoplasmic reticulum calcium
ATPase regulatory protein, renin-angiotensin system
and Connexin-40 (reviewed in15)). Interestingly,
polymorphism of the matrix metalloproteinase-2
(MMP-2) and interleukin-10 (IL-10) genes are also
associated with the prevalence of AF,16) the former
being a possible risk factor, and the latter, a pro-
tective factor against AF. Along with clinical risk
factors such as hypertension or valvular disease,
particular gene polymorphisms may promote AF
development.
Remodeling and inﬂammation
Among the conventional theories dealing with
maintenance of AF, the mechanism of AF is con-
sidered to be a spiral wave with a continuously
changing pattern of the activation wavefront,17,18)
which may be random, multiple re-entry of inde-
pendent wavelets wandering in the atria,19) and be
conducted at various velocities through tissues with
various refractory periods.20) Recently, 85–95% of
asymptomatic adults were shown to have extensions
(‘‘sleeves’’) of atrial myocardium protruding into the
pulmonary veins (PVs).21) Rapidly-ﬁring ectopic
activity in these sleeves around the PV ostia was
described as a new potential mechanism for trigger-
ing AF.22,23) The cause of increased ectopic activity
in PVs is still unclear, although involvement of focal
myocarditis is reported in some patients with focal
atrial tachycardia.24,25)
The persistence of AF leads to changes in atrial
function and structure, which is a plausible explan-
ation for its progressive nature. These changes
promote electrical inhomogeneity, termed electrical
remodeling (e.g. refractory period shortening, loss of
rate adaptation and prolongation of atrial conduction
velocity), and induce structural remodeling charac-
terized by increased connective tissue between
individual cardiomyocytes and deposition of large
amounts of collagen and ﬁbronectin.26,27) These
changes further contribute to maintenance of AF,
a phenomenon known as ‘‘atrial ﬁbrillation begets
atrial ﬁbrillation’’.28) Transforming growth factor-
beta1 (TGF-beta1) is a growth factor involved
in remodelling and may represent one of the main
factors accelerating collagen production in atrial
ﬁbrosis and also associates with clinical types of
AF.29)
Characterization of histological changes in myo-
cardium from patients with AF has been limited
because of tissue availability. Most studies to
investigate alterations in protein and/or gene ex-
pression have usually been performed in animal
models, but on a more limited scale these can also be
performed in humans. In 1991 Frustaci et al. were
the ﬁrst to demonstrate evidence of focal myocarditis
in left ventricular endocardial biopsies from 3 of 14
patients with lone AF.30) Later, they performed right
atrial biopsies, and found that 67% of lone AF
showed the presence of right atrial myocarditis.31)
Recently, maturation of macrophages has been
shown, not in the endocardium of the atrium, but
in the midmyocardium in the left appendages, from
patients with AF and a gradient of maturation from
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endo- to midmyocardium was seen,32) implying that
immature macrophages migrated from the endocar-
dium to the midmyocardium through the processes
of maturation in response to inﬂammation.
Bruins et al. were the ﬁrst to propose that links
between AF and inﬂammation, based on observa-
tions of increased incidence of AF after cardiopul-
monary bypass surgery, which coincided with peak
elevation in systemic C-reactive protein (CRP)
levels.33) The clinical burden of AF has also been
associated with increased CRP levels, which were
highest in the patients with persistent AF34–36) and
which could also predict successful cardioversion in
patients with paroxysmal AF.36) CRP is an acute
phase reactant that is a non-speciﬁc downstream
marker of systemic inﬂammation. It is upregulated at
the transcriptional level by IL-6, IL-1 and TNF, and
is mainly produced in the liver. CRP recognizes a
range of pathogens and membranes of damaged and
necrotic host cells through Ca2þ-dependent binding
speciﬁcity for phosphorylcholine, and plays a role in
host defense against pathogens and clearance of
apoptotic and necrotic cells. It also has signiﬁcant
pro-inﬂammatory properties.37) However, elevated
serum CRP may not reﬂect AF per se but occur
because of confounding underlying cardiovascular
diseases such as hypertension and coronary artery
disease.38)
Increased serum levels of IL-6 and TNF are also
reported in patients with AF, and in particular, the
IL-6 levels are positively related to AF duration.39,40)
Interestingly, in patients with AF, serum IL-6 levels
from the coronary sinus (local cardiac sample) were
not elevated compared to those from the femoral
vein (systemic sample),41,42) suggesting that the
origin of IL-6 appears to be systemic rather than
cardiac. Many cells, including T-lymphocytes, mac-
rophages, monocytes, endothelial cells, adipocytes,
and ﬁbroblasts produce IL-6; among the most
important sources are macrophages and activated
monocytes at inﬂammatory sites.43) Histological
studies indicate the presence of atrial myocarditis
in AF;30) therefore, circulating monocytes activated
in ﬁbrillating atria could be a source of IL-6.
Thrombosis
The occurrence of AF is a high risk for throm-
boembolism, particularly in cerebral stroke, with a
5-fold increase in risk compared to subjects without
AF.44) More than 150 years ago, Rudolf Virchow
proposed a triad of events needed for thrombus
formation, namely, blood ﬂow, abnormal changes of
the vessel wall, and blood constituents.45) In AF, the
three components of Virchow’s triad are fulﬁlled.
The left atrial appendage (LAA), which is long with
a narrow inlet46) that causes blood stasis, is the most
common site of intra-atrial thrombus formation.
Moreover, the absence of organized mechanical
contraction of ﬁbrillating atria, and the presence of
atrial stretch and dilatation contribute to further
stasis. In LAA with AF, severe endocardial changes,
such as edema, ﬁbrinous transformation and small
areas of endothelial denudation are reported.47,48)
Also, patients with AF are in a prothrombotic or
hypercoagulable state, as indicated by the presence
of activated platelets and abnormal hemostatic
constituents indicative of thrombogenesis, such as
prothrombin fragments 1 and 2 (F1+2), thrombin-
antithrombin III complex (TAT) and D-dimer.49–52)
Although the precise mechanisms of thrombo-
genesis remain to be clariﬁed, there is growing
evidence that inﬂammation plays a crucial role
in prothrombotic state in AF. Even patients with
paroxysmal and persistent AF have a risk of stroke
that is similar to that of patients with permanent
AF,53) suggesting that chronic inﬂammation in the
atrium may play a crucial role in a prothrombotic
or hypercoagulable state in patients with AF.11,54)
Moreover, increased levels of pro-inﬂammatory
mediators, such as IL-6 and CRP, may increase the
risk of cardiovascular thrombotic events55) and in
patients with AF, high plasma levels of CRP and
IL-6 are independently related to indices of the
prothrombotic state.56) One plausible mechanism
is that CRP induces monocyte tissue factor (TF), a
potent activator of the extrinsic coagulation cascade,
although it is uncertain whether CRP has direct
prothrombotic eﬀects in AF.57–59) Another mecha-
nism is vascular endothelial growth factor (VEGF),
which is one of the potential drivers for thrombo-
genesis. IL-6 increases platelet production and
sensitivity to thrombin,60) and activated platelets
largely produce VEGF,61) and this was followed by
upregulation of TF mRNA in endothelial cells.62)
In both persistent and permanent AF, VEGF levels
are substantially upregulated with a corresponding
increase in TF,63) and in non-valvular AF, TF
was overexpressed in the endothelia, particularly
in tissues containing inﬂammatory cells.64)
Generally, at inﬂammatory sites, proteases from
the circulation or inﬂammatory cells cleave protease-
activated receptors (PARs), a family of four G-
protein–coupled receptors. The activation of PAR on
numerous cell types including ﬁbroblasts, mono-
cytes/macrophages and vascular endothelial cells,
leads to the induction and release of pro-inﬂamma-
tory mediators such as IL-6 and TNF.65) The most
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thoroughly established activators of PARs are
coagulation proteases thrombin, factor Xa and tissue
factor (TF)–factor VIIa–factor Xa complexes. These
PAR-mediated pro-inﬂammatory responses induce
further expression of TF. Thereby PARs may play a
central role in perpetuating the interplay between
coagulation and inﬂammation (reviewed in66)).
Moreover, thrombin also induces the expression
of endothelial cell adhesion molecules, including
P-selectin and intercellular adhesion molecule-1
(ICAM-1) in vitro and may therefore facilitate the
recruitment of inﬂammatory cells. Thus, the inter-
play between coagulation and inﬂammation may
propagate chronic disease processes.67) Similar proc-
esses could be involved in pathogenesis of AF.
Taken together, these facts imply that thrombo-
genesis develops as a consequence of chronically
inﬂamed atria in AF. Propensity for thrombus
formation may be dependent on circulating TF
expressed on monocytes, leading to activation of
two coagulation proteases—factor Xa and thrombin.
Accordingly, the factor Xa and thrombin inhibitors
would provide an unprecedented opportunity to
investigate pathological mechanisms and new in-
sights in AF.68)
Oxidative stress
Recent clinical and experimental evidence implies
that oxidative stress may also be involved in
electrical and structural remodeling. Many stimuli,
including growth factors and cytokines, induce
production of reactive oxygen species (ROS) from
a variety of cell types, particularly neutrophils and
monocytes. ROS and reactive nitrogen species
(RNS) function both as potentially deleterious, and
as beneﬁcial anti-microbial or cell-signaling mole-
cules. At low concentrations, they can regulate
numerous intracellular signaling pathways,69,70) and
aﬀect expression of a number of genes in monocytes.
For example, H2O2 activates NF-B to upregulate
pro-inﬂammatory cytokines and immune media-
tors.71) However, when produced in excess, ROS
can cause oxidative damage to many vital cell
components, including proteins, lipids, and DNA.
Their prolonged generation promotes cell death and
tissue damage by activation of stress-activated
signaling pathways. In atrial tissues from patients
with persistent AF, there is increased abundance
of oxidative markers,1) although plasma markers of
oxidative stress (selected markers of protein and
lipid oxidation) did not correlate with developing
AF.72) These ﬁndings imply that local myocardial
oxidative stress may contribute to the pathogenesis
of AF. In paroxysmal and chronic AF, nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases
are a primary source of superoxide in human atrial
myocardium,73) similar to that in myocytes and
vascular cells.74) In addition, activated monocytes
and neutrophils may also contribute to generate
superoxide during phagocytosis through activation
of NADPH oxidase.
Myoﬁbrillar creatine kinase,1) an important factor
in myocyte contractility, and several ion channels,
such as L-type calcium channel,75) sodium chan-
nel,76) and ryanodine receptor,77) are sensitive to the
redox state. Therefore, any concomitant dysfunction
of these proteins may contribute to atrial contractile
dysfunction, acting as a link between inﬂammation
and the structural remodeling of the atrium. Further
research is required to explore the pathways gen-
erating oxidative stress and subsequent propagation
of inﬂammatory responses.
Pharmacotherapy
ACEI/ARB
Animal models of AF have been created by rapid
ventricular pacing (chronic heart failure model: CHF
model)78) or catheter ablation of the mitral valve
chordae (mitral regurgitation model).79) The CHF
and mitral regurgitation models both exhibit increas-
ed myocardial interstitial ﬁbrosis. Deposition of
collagen between the myocardial cells interferes
with normal electrical conduction in the atrium by
creating alternative propagation pathways and con-
duction blocks. Clinically, the pathogenesis of AF
in CHF or mitral valve disease is thought to be
attributable to wall stretching and/or increased atrial
pressure and volume. Atrial stretch increases local
synthesis of angiotensin II. Angiotensin-converting
enzyme (ACE) and angiotensin II are both elevated
in atrial tissue,80,81) and the latter may mediate
ﬁbroproliferative pathways through activation of
angiotensin II type 1 (AT-1) receptors and to lead
to interstitial ﬁbrosis in the atrium thereby facilitat-
ing the maintenance of AF. In ﬁbroblasts, mechan-
ical stretching also can induce expression of TGF-
1,82) a major downstream inducer of angiotensin II.
Interestingly, mice with constitutively-active ACE83)
and TGF-184) show focal myocardial ﬁbrosis and
atrial myocardial ﬁbrosis, respectively. In addition,
some clinical reports suggest decreased development
or recurrence of AF in patients with hypertension
who are treated with ACE inhibitors or angiotensin
receptor-blocking agents (ARBs).85–87) In this con-
text, activation of the renin-angiotensin aldosterone
system (RAAS) followed by mechanical stretching
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of the atria may also contribute to the pathological
substrate of AF. Recently, large clinical trials of
valsartan or irbesartan unfortunately failed to dem-
onstrate any advantage to recurrence of AF.88,89) This
may indicate that ARBs has no additional eﬀects to
ACE inhibitors in preventing AF, because 60% of
patients in these studies were pre-treated with ACE
inhibitors.
Statins
There has been increasing interest in the potential
pleiotropic eﬀects of 3-hydroxy-3-methyl-glutaryl-
CoA reductase inhibitors (statins), particularly as
anti-inﬂammatory agents. Although their primary
function is to reduce cholesterol levels, these drugs
are associated with reduced risk of coronary heart
disease and cerebrovascular disease.90–92) In several
clinical studies of AF, statins were shown to have
beneﬁcial eﬀects.93,94) However, results concerning
the prevention of AF are controversial.95,96) The
precise anti-arrhythmic mechanisms of statins in
AF prevention are still unclear, although there are
several possibilities. Statins exert anti-inﬂammatory
actions through their ability to inhibit production of
isoprenoids, which are required for prenylation of
Rho proteins. Thereby statins modulate Rho family
protein subcellular localization, and this aﬀects their
stability and activity. All Rho family members bind
GTP, and most exhibit GTPase activity. Rho family
GTPases are key signal transducers that regulate
leukocyte adhesion molecules on endothelial cells,
such as ICAM-1 and E-selectin, that can be induced
by pro-inﬂammatory mediators or shear stress.97)
Therefore statins are expected to have beneﬁcial
eﬀects in chronically inﬂamed atrium through
inhibition of Rho GTPases.
These mechanisms may help attenuate chronic
inﬂammation in the ﬁbrillating atrium. Statins also
have plaque-stabilizing properties that are mediated
by lipid reduction and suppression of growth of
macrophages expressing matrix metalloproteinases
(MMPs).98,99) MMPs produced by activated macro-
phages degradade extracellular matrix components,
are the driving force behind myocardial matrix
degradation during remodeling.100–103) Thus MMPs
play a pivotal role in causing ﬁbrosis. In AF,
diﬀerential upregulation of particular MMPs and
downregulation in their speciﬁc inhibitors, the
tissue inhibitors of metalloproteinases (TIMPs), are
demonstrated, implying impaired matrix degrada-
tion.104,105) Thus statins may have favorable eﬀects
in structural remodeling in AF.
Multiple studies have demonstrated that statins
lower CRP levels106–108) and attenuate expression
of pro-inﬂammatory mediators including TNF and
IL-1. Statins also downregulate the surface expres-
sion of binding molecules109) and decrease the
proliferation of mononuclear cells in the peripheral
blood.110) Recently, statins were shown to exert
some direct eﬀects on transmembrane ion ﬂuxes by
interacting with the channel proteins that may aﬀect
the electrophysiological properties of atrial mus-
cle.111,112) Moreover, there is evidence suggesting an
interaction between LDL cholesterol and the renin–
angiotensin system,113) which may also contribute
to favorable eﬀects in AF. Taken together, these
pleiotropic eﬀects of statins would represent an
overall anti-inﬂammatory eﬀect in ﬁbrillating atria.
Corticosteroid
It would be reasonable to propose that anti-
inﬂammatory drugs such as steroids would be
therapeutic in patients with AF. Initial glucocorticoid
therapy in AF was performed in patients undergoing
cardiovascular surgery, with conﬂicting results.
Dexamethasone does not aﬀect the incidence of
perioperative AF, although it signiﬁcantly reduced
release of inﬂammatory markers such as IL-6, IL-8
and CRP.114,115) In contrast, in persistent AF, low-
dose glucocorticoid therapy prevents recurrence of
arrhythmia, and reduces CRP levels.116) Recently, a
dose-response meta-analysis showed that in patients
undergoing cardiovascular surgery, corticosteroid
prophylaxis eﬀectively reduced the risk of AF
although this beneﬁt was independent of cortico-
steroid dose.117) Overall, corticosteroids may be
beneﬁcial for AF prophylaxis, but large randomized
controlled trials will be required to conﬁrm this. The
molecular mechanisms of corticosteroid therapy help
us to understand the pathogenesis of AF.
Resolution of inﬂammation in AF
Many consider inﬂammation as an independent
risk factor for initiation and maintenance of AF. The
mechanisms and mediators that initiate the inﬂam-
mation are relatively well understood although
endogenous mechanisms that terminate inﬂamma-
tory responses are less well researched. Generally,
inﬂammation is a salutary and self-limiting response
to insult or injury that is normally resolved with no
detriment to the host. Multiple mechanisms ensure
resolution. For example, macrophages switch phe-
notypes from pro- to anti-inﬂammatory, and addi-
tional mediators of resolution arise. However,
excessive and/or unresolved inﬂammatory responses
cause irreversible tissue remodeling and loss of
function (e.g. chronic inﬂammation).118,119) Impor-
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tantly, along with the genes activated to promote
inﬂammatory responses, programs of genes that
suppress or limit inﬂammation are also activat-
ed.120,121) Characterizing the mediators crucial for
the resolution phase of inﬂammation in AF would be
informative.
Concluding remarks
Possible associations between AF and inﬂamma-
tion are suggested. However, it is still unclear
whether inﬂammation promotes the development of
AF, or if it is a consequence of AF. It is likely that
preexisting inﬂammation initiates the arrhythmia
that subsequently propagates an inﬂammatory
response, thereby leading to persistence of AF.
Although clinical risk factors for AF may be
involved in generating the mediators that initiate
inﬂammation, precise mechanisms remain unclear.
Many studies show that elevation of the serum IL-6
level coincides with AF. However IL-6 promotes the
initial innate immune response to a more sustained,
adaptive immune response, but does not trigger
inﬂammation. IL-6 has many regenerative or anti-
inﬂammatory activities though the activation of
STAT3-mediated signaling pathways, while it also
exhibits pro-inﬂammatory eﬀects by leading to
activation of the immune system through a recruit-
ment of monocytes to the chronically inﬂamed site
like in Crohn’s disease and rheumatoid arthritis.122)
Failure of inﬂammation to resolve may be a key
factor in AF persistence. Further studies are required
to explore mechanisms of resolution in AF. Further
detailed and extensive investigations into the patho-
genesis of AF will yield new insights into how to
develop more eﬀective therapy and prophylaxis for
this condition.
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